Document is current
Any future updates will be listed below
-
Authors
Das, Priyam
Weisenfeld, Dana
Dahal, Kumar
De, Debsurya
Feathers, Vivi
Coblyn, Jonathan S.
Weinblatt, Michael E.
Shadick, Nancy A.
Cai, Tianxi
Liao, Katherine P. http://orcid.org/0000-0002-4797-3200
-
Funding
Funding for this research was provided by:
National Institutes of Health (R21-AR078339, R21-AR078339, R21-AR078339, R21-AR078339, R21-AR078339)
Harold and DuVal Bowen Fund
- License Information
-
More Information
Article History
Received: 23 November 2022
Accepted: 20 May 2023
First Online: 2 June 2023
Declarations
:
: This study was reviewed and approved by the Mass General Brigham Institutional Review Board. Patient consent was waived by the approving ethics committee.
: Not applicable.
: M.W. receives research grant funding from Bristol Myers Squibb, Lilly, Amgen, and Jansen and stock options from Canfite, Inmedix, and Scipher. M.W. has served as a consultant for Abbvie, Aclaris, Amgen, Arena, Bayer, Bristol Myers Squibb, CorEvitas, EQRx, Genosco, Glaxo Smith Kline, Gilead, Horizon, Johnson and Johnson, Lilly, Pfizer, Revolo, Roche, Scipher, Set Point, and Tremeau. N.S. receives research grant funding from Amgen, UCB, Abbvie, BMS, and Genentech.
